Cytochrome P450 inhibitory properties of common efflux transporter inhibitors

Drug Metabolism and Disposition

Volumn 42, Issue 3, 2014, Pages 441-447

  Englund, Gunilla ^a   Lundquist, Patrik ^a,b,c   Skogastierna, Cristine ^a   Johansson, Jenny ^a   Hoogstraate, Janet ^a   Afzelius, Lovisa ^a   Andersson, Tommy B ^b,d   Projean, Denis ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; ELACRIDAR; FUMITREMORGIN C; GEFITINIB; KETOCONAZOLE; MULTIDRUG RESISTANCE PROTEIN; NELFINAVIR; PROBENECID; QUINIDINE; RESERPINE; RITONAVIR; SAQUINAVIR; TACROLIMUS; VERAPAMIL; VERLUKAST; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; DRUG; TUMOR PROTEIN;

ARTICLE; CELL TRANSPORT; CONTROLLED STUDY; DRUG DISPOSITION; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME METABOLISM; FEMALE; HUMAN; HUMAN CELL; LIVER CELL; LIVER MICROSOME; MALE; PRIORITY JOURNAL; CELL CULTURE; CHEMISTRY; CRYOPRESERVATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; ENZYME SPECIFICITY; ENZYMOLOGY; METABOLISM;

ATP-BINDING CASSETTE TRANSPORTERS; CELLS, CULTURED; CRYOPRESERVATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HEPATOCYTES; HUMANS; MALE; MICROSOMES, LIVER; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; SUBSTRATE SPECIFICITY;

EID: 84907261333     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.054932     Document Type: Article

References (44)

1. Badolo L, Trancart MM, Gustavsson L, and Chesné C (2011) Effect of cryopreservation on the activity of OATP1B1/3 and OCT1 in isolated human hepatocytes. Chem Biol Interact 190:165-170.
2. Bankstahl JP, Bankstahl M, Römermann K, Wanek T, Stanek J, Windhorst AD, Fedrowitz M, Erker T, Müller M, and Löscher W, et al. (2013) Tariquidar and elacridar are dose-dependently transported by P-glycoprotein and Bcrp at the blood-brain barrier: a small-animal positron emission tomography and in vitro study. Drug Metab Dispos 41:754-762.
3. 50) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria. Drug Metab Dispos 41:1347-1366.
4. Brown HS, Wilby AJ, Alder J, and Houston JB (2010) Comparative use of isolated hepatocytes and hepatic microsomes for cytochrome P450 inhibition studies: transporter-enzyme interplay. Drug Metab Dispos 38:2139-2146.
5. Brown HS, Chadwick A, and Houston JB (2007) Use of isolated hepatocyte preparations for cytochrome P450 inhibition studies: comparison with microsomes for Ki determination. Drug Metab Dispos 35:2119-2126.
6. Center for Drug Evaluation and Research (CDER) (2006) Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling [Draft Guidance], U.S. Department of Health and Human Services, Food and Drug Administration, Rockville, MD. http://www.fda.gov/OHRMS/DOCKETS/98fr/06d-0344-gdl0001.pdf.
7. Center for Drug Evaluation and Research (CDER) (2012) Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations [Draft Guidance], U.S. Department of Health and Human Services, Food and Drug Administration, Rockville, MD. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf.
8. Elsby R, Hilgendorf C, and Fenner K (2012) Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1. Clin Pharmacol Ther 92:584-598.
9. European Medicines Agency(2012). Guideline on the Investigation of Drug Interactions. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/07/WC500129606.pdf
10. Floby E, Johansson J, Hoogstraate J, Hewitt NJ, Hill J, and Sohlenius-Sternbeck AK (2009) Comparison of intrinsic metabolic clearance in fresh and cryopreserved human hepatocytes. Xenobiotica 39:656-662.
11. Gertz M, Cartwright CM, Hobbs MJ, Kenworthy KE, Rowland M, Houston JB, and Galetin A (2013) Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential. Pharm Res 30:761-780.
12. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, and Hillgren KM, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
13. Grime K, Webborn PJ, and Riley RJ (2008) Functional consequences of active hepatic uptake on cytochrome P450 inhibition in rat and human hepatocytes. Drug Metab Dispos 36:1670-1678.
14. Hallifax D and Houston JB (2006) Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement. Drug Metab Dispos 34:724-726, author reply 727.
15. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, and Kim RB (2006) Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130:1793-1806.
16. Kalvass JC, Polli JW, Bourdet DL, Feng B, Huang SM, Liu X, Smith QR, Zhang LK, and Zamek-Gliszczynski MJ; International Transporter Consortium (2013) Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position. Clin Pharmacol Ther 94:80-94.
17. Khojasteh SC, Prabhu S, Kenny JR, Halladay JS, and Lu AY (2011) Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet 36:1-16.
18. Kilford PJ, Gertz M, Houston JB, and Galetin A (2008) Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data. Drug Metab Dispos 36:1194-1197.
19. Kim KA, Chung J, Jung DH, and Park JY (2004) Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol 60:575-581.
20. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, and Roden DM, et al. (1999) Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 16:408-414.
21. Kimoto E, Yoshida K, Balogh LM, Bi YA, Maeda K, El-Kattan A, Sugiyama Y, and Lai Y (2012) Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes. Mol Pharm 9:3535-3542.
22. Kitamura S, Maeda K, Wang Y, and Sugiyama Y (2008) Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 36:2014-2023.
23. Klaassen CD and Aleksunes LM (2010) Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev 62:1-96.
24. Kurnik D, Wood AJ, and Wilkinson GR (2006) The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity. Clin Pharmacol Ther 80:228-234.
25. Lundquist P, Englund G, Skogastierna C, Lööf J, Johansson J, Hoogstraate J, Afzelius L, and Andersson TB (2014a) Functional ATP-binding cassette drug efflux transporters in isolated human and rat hepatocytes significantly affect assessment of drug disposition. Drug Metab Dispos 42:448-458.
26. Lundquist P, Lööf J, Sohlenius-Sternbeck A-K, Floby E, Johansson J, Bylund J, Hoogstraate J, Afzelius L, and Andersson TB (2014b) The impact of solute carrier (SLC) drug uptake transporter loss in human and rat cryopreserved hepatocytes on clearance predictions. Drug Metab Dispos 42:469-480.
27. Makaji E, Trambitas CS, Shen P, Holloway AC, and Crankshaw DJ (2010) Effects of cytochrome P450 inhibitors on the biotransformation of fluorogenic substrates by adult male rat liver microsomes and cDNA-expressed rat cytochrome P450 isoforms. Toxicol Sci 113:293-304.
28. Masimirembwa CM, Otter C, Berg M, Jönsson M, Leidvik B, Jonsson E, Johansson T, Bäckman A, Edlund A, and Andersson TB (1999) Heterologous expression and kinetic characterization of human cytochromes P-450: validation of a pharmaceutical tool for drug metabolism research. Drug Metab Dispos 27:1117-1122.
29. Mateus A, Matsson P, and Artursson P (2013) Rapid measurement of intracellular unbound drug concentrations. Mol Pharm 10:2467-2478.
30. Matsson P, Pedersen JM, Norinder U, Bergström CA, and Artursson P (2009) Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res 26:1816-1831.
31. Morrissey KM, Wen CC, Johns SJ, Zhang L, Huang SM, and Giacomini KM (2012) The UCSF-FDA TransPortal: a public drug transporter database. Clin Pharmacol Ther 92:545-546.
32. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58.
33. Ozawa N, Shimizu T, Morita R, Yokono Y, Ochiai T, Munesada K, Ohashi A, Aida Y, Hama Y, and Taki K, et al. (2004) Transporter database, TP-Search: a web-accessible comprehensive database for research in pharmacokinetics of drugs. Pharm Res 21:2133-2134.
34. Parkinson A (2001) Biotransformation of xenobiotics, in Casarett and Doull's Toxicology (Klaassen C, ed) pp 133-905, McGraw-Hill, New York.
35. Shitara Y, Li AP, Kato Y, Lu C, Ito K, Itoh T, and Sugiyama Y (2003) Function of uptake transporters for taurocholate and estradiol 17β-D-glucuronide in cryopreserved human hepatocytes. Drug Metab Pharmacokinet 18:33-41.
36. Soars MG, Grime K, Sproston JL, Webborn PJ, and Riley RJ (2007) Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo. Drug Metab Dispos 35:859-865.
37. Soars MG, Webborn PJ, and Riley RJ (2009) Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry. Mol Pharm 6:1662-1677.
38. Sohlenius-Sternbeck AK, Afzelius L, Prusis P, Neelissen J, Hoogstraate J, Johansson J, Floby E, Bengtsson A, Gissberg O, and Sternbeck J, et al. (2010) Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds. Xenobiotica 40:637-649.
39. Stresser DM, Blanchard AP, Turner SD, Erve JC, Dandeneau AA, Miller VP, and Crespi CL (2000) Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 28:1440-1448.
40. Treiber A, Schneiter R, Häusler S, and Stieger B (2007) Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 35:1400-1407.
41. Wacher VJ, Wu CY, and Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-134.
42. Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, and Wood AJ (1999) P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 59:3944-3948.
43. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, and Schuetz EG (2002) Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther 303:323-332.
44. Zhang Y and Benet LZ (2001) The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 40:159-168.